Pulmatrix's Planned Cullgen Merger Terminated, Company Seeks New Strategic Path
PULM sits 39% above its 52-week low of $2.146.
Summary
Pulmatrix announced that Cullgen Inc. terminated their planned merger agreement, effective February 28, 2026, citing significant delays at the China Securities Regulatory Commission. This news directly updates the company's 10-K filed just days prior on February 26, 2026, which detailed the merger as ongoing. The termination of this strategic transaction is a significant setback for the micro-cap biopharmaceutical company, especially given its weak 2025 financials with nil revenue and a $5.162 million net loss. While Pulmatrix states it is actively pursuing alternative merger opportunities, the immediate impact is increased uncertainty regarding its future strategic direction and financial stability. Investors will now closely watch for any announcements regarding new potential partners.
At the time of this announcement, PULM was trading at $2.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.9M. The 52-week trading range was $2.15 to $9.37. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.